Collegium Pharmaceutical (COLL) EBITDA (2014 - 2026)

Collegium Pharmaceutical's EBITDA history runs 13 years deep, the most recent figure standing at $31.4 million for Q1 2026.

• In Q1 2026, EBITDA rose 37.67% year-over-year to $31.4 million; the TTM figure through Mar 2026 stood at $189.3 million (up 32.2% YoY), while the FY2025 annual figure was $183.8 million, up 5.79% from the prior year.
• EBITDA was $31.4 million for Q1 2026 at Collegium Pharmaceutical, down from $60.8 million in the prior quarter.
• In the past five years, EBITDA ranged from a high of $62.1 million in Q3 2025 to a low of -$10.0 million in Q1 2022.
• Historically, EBITDA has averaged $34.3 million across 5 years, with a median of $35.1 million in 2025.
• The sharpest annual moves came in 2022 and 2023: EBITDA plunged 147.26% in 2022, then surged 424.69% in 2023.
• A 5-year view of EBITDA shows it stood at $11.8 million in 2022, then soared by 424.69% to $61.7 million in 2023, then plunged by 38.22% to $38.1 million in 2024, then surged by 59.42% to $60.8 million in 2025, then plunged by 48.39% to $31.4 million in 2026.
• The last three EBITDA figures came in at $31.4 million (Q1 2026), $60.8 million (Q4 2025), and $62.1 million (Q3 2025), per Business Quant data.